Pharmaceutical innovation: Incentives, competition, and cost-benefit analysis in international perspective

Pharmaceutical Innovation: Incentives, Competition, and Cost-Benefit Analysis in International Perspective

Volumn , Issue , 2007, Pages 1-331

  Sloan, Frank A ^a   Hsieh, Chee Ruey ^b  

^a DUKE UNIVERSITY   (United States)

^b INSTITUTE OF ECONOMICS   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84926963273     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511618871     Document Type: Book

References (447)

1. Abramocicz, M. 2003. “Perfecting Patient Prizes.” Vanderbilt Law Review 56(1):114-236
2. Acemoglu, D., and J. Linn. 2004. “Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry.” Quarterly Journal of Economics 119(3):1049–1090
3. Ackerberg, D. 2003. “Advertising, Learning, and Consumer Choice in Experience Good Market: A Structure Examination.” International Economie Review 44:1007-1040
4. Addis, A., and N. Magrini. 2002. “New Approaches to Analysing Prescription Data and Transfer Pharmacoepidemiological and Evidence-Based Reports to Prescribers.” Pharmacoepidemiology and Drug Safety 11:721-726
5. Ades, A. 2003. “A Chain of Evidence with Mixed Comparisons: Models for Multi- parameter Syntheses and Consistency of Evidence.” Statistics in Medicine 22:2995-3016
6. Advanced Markets Working Group. 2005. MakingMarkets for Vaccines: A Practical Plan to Spark Innovation for Global Health. Washington, DC: Center for Global Devel- opment & Global Health Policy Research Network. Available at www.cgdev.org/section/initiatives/_active/vaccinedevelopment/chapters
7. Aghion, Philippe, and Jean Tirole. 1994. “The Management of Innovation.” Quarterly Journal of Economics 109:1185-1209
8. Aikin, Kathryn J. 2003. “The Impact of Direct-to-Consumer Prescription Drug Advertising on the Physician-Patient Relationship.” PowerPoint presentation. Available at www.fda.gov/cder/ddmac/aikin/sld001.htm
9. Almond, D. 2003. “Is the 1918 Influenza Pandemic Over? Long-Term Effects of Utero Influenza Exposure in the Post-1940 U.S. Population.” Available at www.nber.org/~almond. Last accessed January 21, 2005
10. American Psychiatric Association. 2003. Practice Guidelines for the Treatment of Patients with Major Depression. Available at www.psych.org/psycRpract/treatg/pg/Depression2e.book.cfm. Last accessed July 18, 2004
11. Anand, G. 2004. “How Drug’s Rebirth as Treatment for Cancer Fueled Price Rises; Once- Demonized Thalidomide Boosts Celgene’s Sales; Patients See Costs Soar; Avoiding AIDS Activists.” Wall Street Journal, November 15, 2004
12. Anderson, G. F., and P. S. Hussey. 2001. “Comparing Health System Performance in OECD Countries.” Health Affairs 20(5):219-232
13. Anderson, G. F., U. E. Reinhardt, P. S. Hussey, and Varduhi Petrosyan. 2003. “It’s the Prices, Stupid: Why the United States Is So Different from Other Countries.” Health Affairs 22(3):89–105
14. Ange U Marcia. 2004. The Truth about the Drug Companies: How They Deceive Us and Whatto Do about It. New York: Random House
15. Anis A. H., and Y. Gagnon. 2000. “Using Economie Evaluations to Make Formulary Coverage Decisions: So Much for Guidelines.” PharmacoEconomics 18:55-62
16. Anon, N. D. 2005. “The History ofthe Pasteur Institute.” Paris: Pasteur Institute. Available at www.pasteur.fr/english.html
17. Anton, J. J., and D. A. Yao. 1987. “Second Sourcing and the Experience Curve: Price Competition in Defense Procurement.” Rand Journal of Economics 18(1):57–76
18. Anton, J. J., and D. A. Yao. 1989. “Split Awards, Procurement, and Innovation.” Rand Journal ofEconomics 20(4):538–552
19. Arnould, R., and L. DeBrock 2002. “An Overview ofthe Market for Vaccines in the United States.” Unpublished. Available from the Institute of Medicine, Washington, DC
20. Arrow, Kenneth J. 1963. “Uncertainty and the Welfare Economics of Medical Care.” American EconomicReview 53(5):941–973
21. Avorn, Jerry. 2003. “Advertising and Prescription Drugs: Promotion, Education, andthe Public Health.” Health Affairs - Web Exclusive W3:104–108
22. Avorn, Jerry. 2004. PowerfulMedicines: TheBenefits, Risks, and Costs of Prescription Drugs. New York: Alfred A. Knopf
23. Azoulay, Pierre. 2004. “Capturing Knowledge within and across Firm Boundaries: Evi- dence from Clinical Development.” American Economic Review 94 (5):1591–1612
24. Babazono, Akira, and Alan L. Hillman. 1994. “A Comparison of International Health Outcomes and Health Care Spending.” International Journal of Technology Assessment in Health Care 10(3):376–381
25. Bagwell, Kyle, ed. 2001. The Economics of Advertising. International Library of Critica! Writings in Economics, vol. 136. Cheltenham, U.K.: Edward Elgar Publishing
26. Bain & Company. 2005. “The Pharma Innovation Divide: The High Cost of Europe’s ‘Free Ride.’” Available at www.bain.com/bainweb/Consulting_Expertise/hot_topics/detail.asp?id=22. Last accessed October 28, 2005
27. Baines, Darrin L, Keith H. Tally, and David K. Whynes. 1997. Prescribing Budgets and Fundholding in General Practice. London: Office of Health Economics
28. Batchlor, Elaine, and Marianne Laouri. 2003. “Pharmaceutical Promotion, Advertising, and Consumers.” Health Affairs - Web Exclusive W3:109–115
29. Bear Stearns. 2002. “Attack of the Clones: 18 Years past Waxman-Hatch.” October 2. New York: Bear Stearns
30. Becker, Elizabeth. 2003. “U.S. Is Battling for Higher Drug Prices Overseas.” New York Times, November 28
31. Becker, Gary S., Thomas J. Phillipson, and Rodrigo R. Soares. 2005. “The Quantity and Quality of Life and the Evolution of World Inequality.” American Economic Review95(1):277–291
32. Benkler, Y. 2004. “Commons Based Strategies and the Problems of Patents.” Science305:1110–1111
33. Berndt, Ernst R. 2001. “The U.S. Pharmaceutical Industry: Why Major Growth in Times of Cost Containment?” Health Affairs 20(2):100–114
34. Berndt, E. R. 2002. “Pharmaceuticals in U.S. Health Care: Determinants of Quality and Price.” Journal of Economie Perspectives 16(4):45-66
35. Berndt, Ernst R. 2005. “To Inform or Persuade? Direct-to-Consumer Advertising of Prescription Drugs.” New England Journal of Medicine 352(4):325-328
36. Berndt, Ernst R., Ashoke Bhattacharjya, David Mishol, Almudena Arcelus, and Thomas Lasky. 2002. “An Analysis of the Diffusion of New Antidepressants: Variety, Quality, and Marketing Efforts.” Journal of Mental Health Policy and Economics 5(1):3–17
37. Berndt, Ernst R., Iain M. Cockburn, and Karen A. Grepin. 2005. “Biopharmaceutical R&D: Is the Productivity Decline Overstated?” Working paper, Conference on Health Reform in Europe and the U.S., Tufts Center, Talloues, France, July 2005
38. Berndt, E., R. Glennerster, M. R. Kremer, J. Lee, R. Levine, G. Weizsacker, and H. Williams. 2005. “Advanced Markets for a Malaria Vaccine: Estimating Costs and Effectiveness.” National Bureau of Economic Research Working Paper 112-88
39. Berndt, E. R., and J. A. Hurwitz. 2005. “Vaccine Advance Purchase Agreements for Low- Income Countries: Practical Issues.” Health Affairs 24(3):653-665
40. Berndt, Ernst R., Margaret K. Kyle, and Davina C. Ling. 2003. “The Long Shadow of Patent Expiration: Generic Entry and Rx to OTC Switches.” Chapter 8 in Scanner Data and Price Indexes, NBER Series on the Conference on Research in Income and Wealth, vol. 61, ed. by Robert C. Feenstra and Matthew D. Shapiro, 229-267. Chicago: University of Chicago Press for the National Bureau of Economic Research
41. Beutels, P., W. J. Edmunds, F. Antonanzas, G. A. de Wit, D. Evans, R. Feilden, A. M. Fendrick, et al. 2002. “Economic Evaluation of Vaccination Programmes: A Consensus Statement Focusing on Viral Hepatitis.” Pharmaco Economics 20:1-7
42. Birch, S., and A. Gafni. 2002. “On Being NICE in the UK: Guidelines for Technology Appraisal for the NHS in England and Wales.” Health Economics 11:185-191
43. Black, Douglas J., Cyril Smith, and Peter Townsend. 1982. Inequalities in Health: The Black Report. New York: Penguin Books
44. Bloom, B. D. J. Wiertz, and M. Pauly. 1986. “Cost and Price of Comparable Brandedand Generic Pharmaceuticals.” Journal of the American Medical Association 256(18):2523-2530
45. Boardman, Anthony, Ruth Freedman, and Catherine Eckel. 1986. “The Price of Government Ownership: A Study of the Domtar Takeover.” Journal of Public Economics31(3):269-286
46. Boardman, Anthony E., and Aidan R. Vining. 1989. “Ownership and Performance in Competitive Environments: A Comparison of the Performance of Private, Mixed, and State-Owned Enterprises.” Journal of Law and Economics 32(1):1–33
47. Boswell, C. 2003. “InnoCentive and Web-Based Collaborative Innovation.” Chemical Market Reporter, April 14
48. Bradford, D. F., and D. N. Shaviro. 2000. “The Economics of Vouchers,” in Vouchers and the Provision of Public Services, ed. by C. E. Steuerle, Van Doorn Ooms, George Peterson, and Robert D. Reischauer, 606-607. Washington, DC: Brookings Institution Press
49. Branstetter, Lee G., Raymond Fisman, and C. Fritz Foley. 2003. “Do Stronger Intellec- tual Property Rights Increase International Technology Transfer? Empirical Evidence from U.S. Firm-Level Panel Data.” Unpublished paper, Columbia University Business School
50. Breyer, S. 1982. Regulation and Its Reform. Cambridge, MA: Harvard University Press
51. Brito, D. L., E. Sheshinski, and M. D. Intriligator. 1991. “Externalities and Compulsory Vaccinations.” Journal of Public Economics 45:69-90
52. Caffrey, Andrew. 2002. “Why Generics Can Cost States More Money.” Wall Street Journal, February 13
53. Calfee, John E. 2002. “Public Policy Issues in Direct-to-Consumer Advertising of Prescription Drugs.” Journal of Public Policy & Marketing 21(2):174–193
54. Calfee, John E. 2003. “What Do We Know about Direct-to-Consumer Advertising of Prescription Drugs?” Health Affairs - Web Exclusive W3:116-119
55. Calfee, John E. 2004. “Paying for the Pills: How Much Does It Really Cost to Put a New Drug on the Market?” Nature 429: 807
56. Calfee, John E., Clifford Winston, and Randolph Stempski. 2002. “Direct-to-Consumer Advertising and the Demand for Cholesterol-Reducing Drugs.” Journal ofLaw and Economics 14(2):673-690
57. Carlton, Dennis W., and Jeffrey M. Perloff. 1994. Modern Industrial Organization. 2nd ed. New York: HarperCollins College Division
58. Caro J., W. Klittich, A. McGuire, and I. Ford. 1997. “The West of Scotland Coronary Prevention Study: Economic Benefit Analysis of Primary Prevention with Pravastatin.” British Medical Journal 315:1577-1582
59. Caves, R. E., M. D. Whinston, and M. Hurwitz. 1991. “Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry.” Brookings Papers on Economic Activity Microeconomics (1991):1-66
60. Center for Global Development Advanced Market Commitment Working Group. 2005. “Making Markets for Vaccines: Ideas to Action.” Available at www.cgdev.org/Publications/vaccine/_files/MakingMarkets-complete.pdf. Last accessed April 28, 2005
61. Claxton K., L. Ginnelly, M. Sculpher, Z. Philips, and S. Palmer. 2004. “A Pilot Study on the Use of Decision Theory and Value of Information Analysis as Past of the National Health Service Technology Assessment Programme. Health Technology Assessment 8(31) (wholeissue)
62. Clissold, D. B. 1995. “Prescription for The Orphan Drug-Act: The Impact ofthe FDA’s 1992 Regulations and the Latest Congressional Proposals for Reform.” Food and Drug Law Journal 50(1):125–147
63. Cochrane, A. L., A. S. St. Leger, and F. Moore. 1978. “Health Service ‘Input’ and Mortality ‘Output’ in Developed Countries.” Journal of Epidemiology and Community Health32(3):200-205
64. Cockburn, Iain M. 2004. “The Changing Structure of the Pharmaceutical Industry.” Health Affairs 23:10-22
65. Cockburn, Iain, and Rebecca Henderson. 1994. “Racing to Invest? The Economics of Competition in Ethical Drug Discovery.” Journal of Economics and Management Strat- egy 33:481-519
66. Cockburn, Iain, and Rebecca Henderson. 1996. Scale, Scope, and Spillovers: The Deter- minants of Research Productivity in Drug Discovery. Rand Journal of Economics 27: 32-60
67. Cockburn, Iain M., and Rebecca M. Henderson. 1998. “Absorptive Capacity, Co- Authoring Behavior, and the Organization of Research in Drug Discovery.” Journal of Industrial Economics 46:157-182
68. Cockburn, Iain, and Rebecca Henderson. 1999. “The Economics of Drug Discovery,” in Ralph Landau et al., eds., Pharmaceutical Innovation, 308-330. Philadelphia: Chemical Heritage Press
69. Cockburn, Iain, and Rebecca Henderson. 2001. “Scale and Scope in Drug Development: Unpacking the Advantages of Size in Pharmaceutical Research.” Journal of Health Economics 20(6):1033-1057
70. Cockburn, Iain M., Rebecca Henderson, and Scott Stern. 1999. “The Diffusion of Sci- ence Driven Drug Discovery, Organizational Change in Pharmaceutical Research.” National Bureau of Economic Research Working Paper 7359
71. Cohen, J. 2002. “US Vaccine Supply Falls Seriously Short.” Science 295(55-62):1998-2001
72. Cohen, J. 2004. “Vaccine Policy: Immunizing Kids against Flu May Prevent Deaths among the Elderly.” Science 306(5699):11-23
73. Cohen, W. M., and S. A. Merrill. 2003. Patents in the Knowledge-Based Economy: Com- mittee on Intellectual Property Rights in the Knowledge-Based Economy. Washington, DC: National Academies Press, National Research Council (U.S.)
74. Cohen, Wesley M., Richard R. Nelson, and John P. Walsh. 2002. “Protecting Their Intellectual Assets: Appropriability Conditions and Why U.S. Manufacturing Firms Patent (Or Not).” National Bureau of Economic Research Working Paper 7552
75. Comanor, William S. 1964. “Research and Competitive Product Differentiation in the Pharmaceutical Industry in the United States.” Economica 31:372-384
76. Comanor, William S. 1965. “Research and Technical Change in the Pharmaceutical Industry.” Review of Economics and Statistics 47(2):182-190
77. Conroy, Robert, Robert Harris, and Thomas Massaro. 1992. “Assessment of Risk and Capital Costs in the Pharmaceutical Industry.” Unpublished paper, University of Virginia, Darden School, June 30
78. Corrigan, J. M., A. Greiner, and S. M. Erickson, eds. 2002. Fostering Rapid Advances in Health Care: Learning from System Demonstrations. Washington, DC: National Academies Press
79. Covert, N. 2000. “Cutting Edge: A History of Fort Detrick.” Frederick, MD: Self- published. Available at www.detrick.army.mil/detrick/cutting_edge/index.cfm? chapter 12
80. Crawford, Gregory S., and Matthew Shum. 2005. “Uncertainty and Learning in Pharmaceutical Demand.” Econometrica 73(4):4
81. Cremieux, Pierre-Yves, Marie-Claude Meilleur, Pierre Ouellette, Patrick Petit, Martin Zelder, and Ken Potvin. 2005. “Public and Private Pharmaceutical Spending as Deter- minants of Health Outcomes in Canada.” Health Economics 14:107-116
82. Cremieux, Pierre-Yves, Pierre Ouellette, Marie-Clause Meilleur, Stephanie Leong, Paul Greenberg, and Howard Birnbaum. 2001. “Pharmaceutical Spending and Health Outcomes in the United States,” in Investing in Health: The Social and Economic Benefits of Health Care Innovation,” ed. by Irina Farquhar, Kent Summers, and Alan Sorkin, 59-76. Oxford: Elsevier Science
83. Cremieux, Pierre-Yves, Pierre Ouellette, and Caroline Pilon. 1999. “Health Care Spending as Determinants of Health Outcomes.” Health Economics 8:627-639
84. Currie, J., and Brigitte C. Madrian. 1999. “Health, Health Insurance and the Labor Market,” in Handbook of Labor Economics, ed. by Orley Ashenfelter and David Card, 3309-3415. Amsterdam: Elsevier Science
85. Cutler, David M. 2004. Your Money or Your Life: Strong Medicine for America’s Health Care System. New York: Oxford University Press
86. Cutler, David M., Angus S. Deaton, and Adriana Lleras-Muney. 2006. “The Determi- nants of Mortality.” Journal of Economic Perspective 20(3):97–120
87. Cutler, David M., and Srikanth Kadiyala. 2003. “The Return to Biomedical Research: Treatment and Behavioral Effects,” in Measuring the Gainsfrom Medical Research: An Economic Approach, ed. by Kevin M. Murphy and Robert H. Topel, 110–162. Chicago: University of Chicago Press
88. Cutler, David M., and Mark McClellan. 2001a. “Is Technological Change in Medicine Worth It?” Health Affairs 20(5):11–29
89. Cutler, D. M., and M. McClellan. 2001b. “Productivity Change in Health Care.” American Economic Review 91(2):281–286
90. Cutler, David, Mark McClellan, and Joseph Newhouse. 1997. “The Costs and Benefits of Intensive Treatment for Cardiovascular Disease.” Paper presented at AEI-Brookings Conference on Measuring the Prices of Medical Treatments, December 12
91. Cutler, David, and Elizabeth Richardson. 1997. “Measuring the Health of the U.S. Pop- ulation.” Brookings Papers on Economic Activity: Microeconomics (1997):217–271
92. Cutler, David M., and R. Zeckhauser. 2000. “The Anatomy of Health Insurance,” in Handbook of Health Economics, ed. by Antony J. Culyer and Joseph P. Newhouse, 563–643. Amsterdam: Elsevier
93. Danzon, Patricia M. 2000. “Pharmaceutical Benefit Management: An Alternative Approach.” Health Affairs 19(1):24–25
94. Danzon, Patricia M. 2001. “Reference Pricing: Theory and Evidence,” in ReferencePricing and Pharmaceutical Policy, ed. by G. López-Casasnova and B. Jönsson, 86–126
95. Danzon, P. 2002. PharmaceuticalPriceRegulation: National Policies versus Global Interests. Washington, DC: AEI Press
96. Danzon, Patricia M., and Li-Wei Chao. 2000. “Does Regulation Drive Out Competition in Pharmaceutical Markets?” Journal of Law and Economics 42(2):311–357
97. Danzon, Patricia M., and Michael Furukawa. 2003. “Prices and Availability of Pharma- ceuticals: Evidence from Nine Countries.” Health Affairs - Web Exclusive W3:521–536
98. Danzon, Patricia M., Sean Nicholson, and Nuno Sousa Pereira. 2005. “Productivity in Pharmaceutical-Biotechnology R&D: The Role of Experience and Alliances.” Journal of Health Economics 24:317–339
99. Danzon, P. M, N. S. Pereira, and S. S. Tejwani. 2005. “Vaccine Supply: A Cross-National Perspective.” Health Affairs 24(3):706–717
100. Danzon, Patricia M., Y. Richard Wang, and Liang Wang. 2005. “The Impact of Price Regulation on the Launch Delay of New Drugs: Evidence from 25 Markets in the 1990s.” Health Economics 14:269–292
101. Davidson, G., L. A. Blewett, K. T. Call, and SHADA Center. 2004. “Public Program Crowd-out of Private Coverage: What Are the Issues?” Research Synthesis Report No. 5. Available at www.rwjf.org/publications/synthesis/reports_and_briefs/issue5.html
102. Davis, M. M., S. M. Ndiaye, G. L. Freed, C. S. Kim, and S. J. Clark. 2003. “Influence of Insurance Status and Vaccine Cost on Physicians’ Administration of Pneumococcal Conjugate Vaccine.” Pediatrics 112(3):521–526
103. Davis, M. M., J. L. Zimmerman, J. R. C. Wheeler, andG. L. Freed. 2002. “Childhood Vaccine Purchase Costs in the Public Sector: Past Trends, Future Expectations.” American Journal of Public Health 92(12):1982–1987
104. DeLaat, E. A. A. 1997. “Patents or Prizes: Monopolistic R&D and Asymmetric Information.” International Journal of Industrial Organization 15(3):369-390
105. Depression Guideline Panel. 1993. Depression in Primary Care: Treatment of Major Depression. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research
106. Dickson, Michael, and Jean Paul Gagnon. 2004. “Key Factors in the Rising Cost of New Drug Discovery and Development.” Nature Reviews 3:417-428
107. DiMasi, J. A., R. W. Hansen, and H. G. Grabowski. 2003. “The Price of Innovation: NewEstimates of Drug Development Costs.” Journal of Health Economics 22(2):151-185
108. DiMasi, J. A., R. W. Hansen, H. G. Grabowski, andL. Lasagna. 1991. “Cost of Innovation in the Pharmaceutical Industry.” Journal of Health Economics 10(2):107–142
109. Dion, M. R., and L. Pavetti. 2000. Access to and Participation in Medicaid and the Food Stamp Program: A Review of the Recent Literature. Washington, DC: Mathematica Policy Research
110. Donaldson C., G. Currie, and C. Mitton. 2002. “Cost-Effectiveness Analysis in Health Care: Contraindications.” British Medical Journal 325:891-894
111. Donohue, Julie M. 2003. “The Evolving Roles of Consumers and Consumer Protection: The History of Prescription Drug Advertising.” Milbank Quarterly 84(4):659-694
112. Donohue, Julie M., and Ernst R. Berndt. 2004. “Effect of Direct-to-Consumer Advertising on Medication Choice: The Case of Antidepressants.” Journal of Public Policy & Marketing 23(2):115–127
113. Donohue, Julie M., Ernst R. Berndt, Meredith Rosenthal, Arnold M. Epstein, and Richard Frank. 2004. “Effects of Pharmaceutical Promotion on Adherence to Guideline Treatment of Depression.” Medical Care 42(2):1176-1185
114. Dorfman, Robert, and Peter O. Steiner. 1954. “Optimal Advertising and Optimal Quality.” American Economic Review 44(5):826-836
115. Dornbusch, Rudiger, and Stanley Fischer. 1994. Macroeconomics. 6th ed. New York: McGraw-Hill
116. Downs, Anthony. 1957. An Economic Theory of Democracy. New York: HarperCollins College Division
117. Drummond, M. F., and F. Pang. 2001. “Transferability of Economic Evaluation Results.” In Economic Evaluation in Health Care: Merging Theory with Practice, ed. by M. F. Drummond and A. McGuire, 256-327. Oxford: Oxford University Press
118. Drummond, M. F., and M. J. Sculpher. 2005. “Common Methodological Flaws in Economic Evaluations.” Medical Care 43(4):5-14
119. Drummond, M. F., M. J. Sculpher, G. W. Torrance, B. J. O’Brien, and G. L. Stoddart. 2005. Methods for the Economic Evaluation of Health CareProgrammes. 3rded. Oxford: Oxford University Press
120. D’Souza, Juliet, and William L. Megginson. 1999. “The Financial andOperating Performance of Privatized Firms during the 1990s.” Journal of Finance 54(4):1397-1438
121. Dubois, Robert W. 2003. “Pharmaceutical Promotion: Don’t Throw the Baby Out with the Bathwater.” Health Affairs - Web Exclusive W3:96-103
122. Dubois, Robert W., Anita J. Chawla, Cheryl A. Neslusan, et al. 2000. “Explaining Drug Spending Trends: Does Perception Match Reality?” Health Affairs 19:231-239
123. Duggan, Mark. 2005. “Do New Prescription Drugs Pay for Themselves? The Case of Second-Generation Antipsychotics.” Journal of Health Economics 24:1-31
124. Ehrlich, Isaac, Georges Gallais-Hamonno, Zhiqiang Liu, and Randall Lutter. 1994. “Pro- ductivity Growth and Firm Ownership: An Analytical and Empirical Investigation.” Journal of Political Economy 102(5):1006-1038
125. Ellison, G. S., and F. Ellison. 2000. “Strategic Entry Deterrence and the Behavior of Pharmaceutical Incumbents Prior to Patent Expiration.” Working paper, MIT, Cambridge, MA
126. Ellison, Sara Fisher, and Wallace P. Mullin. 1997. “Gradual Incorporation of Information into Stock Prices: Empirical Strategies.” National Bureau of Economic Research Working Paper 6218
127. Emmons, Willis A., and Ashok Nimgade. 1991. “Burroughs Wellcome and AZT.” Harvard Business School Case No. 9-792-004, Cambridge, MA
128. Enserink, M. 2004. “Influenza: Crisis Underscores Fragility of Vaccine Production System.” Science 306(5695):385
129. EPIC Investigators. 1994. “Use of Monoclonal Antibody Directed against the Platelet Glycoprotein lib/111a Receptor in High-Risk Coronary Angioplasty.” New England Journal of Medicine 330:956-961
130. Fama, E. F. 1980. “Agency Problems and the Theory of the Firm.” Journal of Political Economy 88(2):288-307
131. Fama, E. F., L. Fisher, M. Jensen, and R. Roll. 1969. “The Adjustment of Stock Prices to New Information.” International Economic Review 10(1):1–21
132. Farber, Henry S., and Max H. Brazerman. 1986. “The General Basis ofArbitrator Behavior: An Empirical Analysis ofConventional and Final-Offer Arbitration.” Econometrica54:819-844
133. Farlow, A. 2004. “Analysis of the Problems of R&D Finance for Vaccines and an Appraisal of Advance Purchase Commitments.” Preprint. Oxford: University of Oxford. Available at www.economics.ox.ac.uk/members/andrew.farlow/VaccineRD.pdf#search=’farlow%20and%20analysis%20of%20the%20problems
134. Farlow, Andrew, Donald W. Light, Richard T. Mahoney, and Roy Widdus. 2005. “Con- cerns Regarding the ‘Making Markets for Vaccines’ Submission to the Commis- sion on Intellectual Property Rights, Innovation and Public Health.” Available at www.who.int/intellectualproperty/en/. Last accessed May 10, 2005
135. Farquhar, Irina, Kent Summers, and Alan Sorkin, eds. 2001. Benefits of Health Care Innovation. Oxford: Elsevier Science
136. Federal Trade Commission. 2002. Generic Competition Prior to Patent Expiration: An FTC Study. Washington, DC: Federai Trade Commission
137. FinFacts. Global/World Income per Capita/Head 2005. 2005. Available at www.finfacts.com/biz10/globalworldincomepercapita.htm. Last accessed October 20, 2005
138. Finkel, M., and L. Buron. 2001. Study on Section 8 Voucher Success Rates. Cambridge, MA: Diane Publishing
139. Finkelstein, A. 2004. “Static and Dynamic Effects of Health Policy: Evidence from the Vaccine Industry.” Quarterly Journal of Economics 119(2):527-564
140. Forbes, Steve. 2005. “Rich Freeloader Countries - France, German, Canada - Rob America on Health Care.” USA Next. Available at www.usanext.org/fulLstory.cfm?areticleJd=16&category_id=3. Last accessed October 30, 2005
141. Fortune Magazine. 2005. The 2005 Fortune 500: Most Profitable Industries: Return on Revenues. Available at www.fortune.com/fortune/subs/fortune500/topperformers/industrysnapshot/0,23619, prof_pct_rev,00.html
142. Frank, John W., and J. Fraser Mustard. 1998. “The Determinants of Health from a Historical Perspective.” The Founders’ Network. Available at www.founders.net/fn/papers.nsf
143. Frank, R. G., C. Dewa, E. Holt, et al. 1995. “The Demand for Childhood Immunizations: Results from the Baltimore Immunization Study.” Inquiry 32(2):164–173
144. Frank, R. G., and D. S. Salkever. 1992. “Pricing, Patent Loss and the Market for Pharma- ceuticals.” Southern Economic Journal 59:165–179
145. Frank, R. G., and D. S. Salkever. 1997. “Generic Entry and Pricing of Pharmaceuticals.” Journal of Economics and Management Strategy 6(1):75–90
146. Frech, H. E., III, and Richard D. Miller, Jr. 1999. The Productivity of Health Care and Pharmaceuticals: An International Comparison. Washington, DC: AEI Press
147. Freed, G. L., S. J. Clark, D. E. Pathman, R. Schectman, and J. Serling. 1999. “Impact of NorthCarolina’s Universal Vaccine Purchase Program by Children’s Insurance Status.” Archives ofPediatric and Adolescent Medicine 153(7):748–754
148. Freed, G., and A. Cowan. 2002. “State-Level Perspectives on Vaccine Purchase Financing.” Unpublished. Available from the Institute of Medicine, Washington, DC
149. Freed, G. L., M. M. Davis, M. C. Andreae, S. Bass, and H. Weinblatt. 2002. “Reimburse- ment for Prevnar: A Modern-Day Version of Hercules and the Hydra.” Pediatrics110(2):399–400
150. Fuchs, Victor R., and Richard Zeckhauser. 1987. “Valuing Health: A ‘Priceless’ Com- modity.” American Economic Review 77(2):263–268
151. Gafni A., and S. Birch. 1993. “Guidelines for the Adoption of New Technologies: A Pre- scription for Uncontrolled Growth in Expenditures and How to Avoid the Problem.” Canadian Medical Association Journal 148(6):913–917
152. Gahart, Martin T., Louise M. Duhamel, Anne Dievler, and Roseanne Price. 2003. “Exam- iningthe FRDA’s Oversight of Direct-to-Consumer Advertising.” Health Affairs-Web Exclusive W3:120–123
153. Gallini, N., and S. Scotchmer. 2002. “Intellectual Property: When Is It the Best Incentive Mechanism?” in Innovation Policy and the Economy, ed. by A. Jaffe, J. Lerner, and S. Stern, 2:51–78. Cambridge, MA: MIT Press
154. Gambardella, Alfonso. 1995. Science and Innovation: The U.S. Pharmaceutical Industry duringthe 1980s. Cambridge: Cambridge University Press
155. George, B., A. Harris, and A. Mitchell. 2001. “Cost-Effectiveness Analysis andthe Consis- tency of Decision-Making: Evidence from Pharmaceutical Reimbursement in Australia (1991 to 1996).” Pharmaco Economics 19(11):1103–1109
156. Georges, P., A. Ann Margaret, P. D. Jeffrey, D. D. Michael, et al. 2003. “Strengthening the Supply of Routinely Recommended Vaccines in the United States: Recommendations from the National Vaccine Advisory Committee.” Journal of the American Medical Association 290(23):3122–3128
157. Giaccotto, Carmelo, Rexford E. Santerre, and John A. Vernon. 2005. “Drug Prices and Research and Development Investment Behavior in the Pharmaceutical Industry.” Journal ofLaw and Economics 48(1):195–214
158. Giffin, R., K. Stratton, and R. Chalk. 2004. “Childhood Vaccine Finance and Safety Issues.” Health Affairs 23(5):98–111
159. Glassman, James K. 2005. “Free Riding Isn’t Free.” Available at www.techcentralstation.com/022304F.html. Last accessed October 28, 2005
160. Glied, Sherry. 2003. “Health Care Costs: On the Rise Again.” Journal of Economic Per- spective 17(2):125–148
161. Global Alliance for TB Drug Development. 2001. Economics of TB Drug Development. New York: Global Alliance for TB Drug Development. Available at http://66.216.124.114/pdf/Economics%20Report%20Full%20(final).pdf
162. Global Health Policy Research Network. 2004. “Making Markets for Vaccines.” Pull Mechanisms Working Group. Available at www.cgdev.org/globalhealth/proj_pull.cfm
163. Gold, M., J. E. Siegel, L. B. Russell, and M. C. Weinstein, eds. 1996. Cost Effectiveness in Health and Medicine. Oxford: Oxford University Press
164. Goodman, J. C., andG. L. Musgrave. 1987. Freedom of Choice in Health Insurance. Dallas: National Center for Policy Analysis
165. Goolsbee, Austan. 1988. “Does Government R&D Policy Mainly Benefit Scientists and Engineers?” American Economic Review 88(2):298-302
166. Grabowski, Henry. 2004. “Are the Economics of Pharmaceutical R&D Changing? Pro- ductivity, Patents and Politicai Pressures.” PharmacoEconomics 22(Suppl. 2):15-24
167. Grabowski, Henry. 2005. “Encouraging the Development of New Vaccines.” Health Affairs 24(3):697-700
168. Grabowski, Henry, Iain Cockburn, and Genia Long. 2006. “The Market for Follow-On Biologics: How Will It Evolve.” Health Affairs 25(5):1291–1301
169. Grabowski, Henry, and Margaret Kyle. 2006. “Generic Competition and Market Exclusivity Periods in Pharmaceuticals.” Managerial and Decision Economics, forthcoming
170. Grabowski, Henry, and C. Daniel Mullins. 1997. “Pharmacy Benefit Management Cost- Effectiveness Analysis and Drug Formulary Decisions.” Social Science and Medicine45(4):535-544
171. Grabowski, Henry, and John Vernon. 1986. “Longer Patents for Lower Imitation Barriers: The 1984 Drug Act.” American Economic Review: Papers and Proceedings 76(2):195-198
172. Grabowski, Henry, and John M. Vernon. 1990. “A New Look at the Return and Risks to Pharmaceutical R&D.” Management Science 36:804-821
173. Grabowski, Henry, and John Vernon. 1992. “Brand Loyalty Entry and Price Competition in Pharmaceuticals after the 1984 Act.” Journal ofLaw and Economics 35(2):331-350
174. Grabowski, Henry, and John M. Vernon. 1994. “Returns on New Drug Introductions in the 1980s.” Journal of Health Economics 13:383-406
175. Grabowski, Henry, and John Vernon. 1996. “Longer Patents for Increased Generic Competition: The Waxman-Hatch Act after One Decade.” Pharmaco Economics 10 (Suppl. 2):110-123
176. Grabowski, Henry, and John Vernon. 2000. “Effective Patent Life in Pharmaceuticals.” International Journal of Technology Management 19(1-2):98-120
177. Grabowski, Henry, John M. Vernon, and Lacy Glenn Thomas. 1978. “Estimating the Effects of Regulation on Innovation: An International Comparative Analysis of the Pharmaceutical Industry.” Journal of Law and Economics 21(1):133-163
178. Grabowski, Henry, and Richard Wang. 2006. “The Quantity and Quality of Worldwide New Drug Introductions:1982-2003.” Health Affairs 25(2):452-460
179. Greene, Jeremy A. 2004. “Attention to ‘Details’: Etiquette and the Pharmaceutical Sales- man in Postwar America.” Social Studies in Science 34(2):271-292
180. Gruber, J. 1994. “The Incidence of Mandated Maternity Benefits.” American Economic Review 84(3):622-642
181. Gruber, J., ed. 2000. “Health Insurance and the Labor Market,” in Handbook ofHealth Economics, ed. by Antony J. Culyer and Joseph P. Newhouse, 645-706. Amsterdam: Elsevier Science
182. Guedj, Ilan, and David Scharfstein. 2004. “Organizational Scope and Investment: Evidence from the Drug Development Strategies of Biopharmaceutical Firms.” National Bureau of Economic Research Working Paper
183. Gupta, Nandini. 2002. “Partial Privatization and Firm Performance.” Unpublished working paper, Columbia University. August. Available at www-1.gsb.columbia.edu/divisions/management/seminar/papers/gupta.pdf
184. Hall, Bronwyn H. 1993, “R&D Tax Policy during the Eighties: Success or Failure?” in Tax Policy and the Economy 7, ed. by James Poterba, 1-35. Cambridge, MA: MIT Press
185. Hall, Bronwyn H., and John van Reenen. 2000. “How Effective Are Fiscal Incentives for R&D? A New Review of the Evidence.” Research Policy 29:449-469
186. Hall, Robert E., and Charles I. Jones. 1999. “Why Do Some Countries Produce So Much More Output per WorkerthanOthers?” Quarterly Journal of Economics 114(1):83-116
187. Hansen, Ronald W. 1979. “The Pharmaceutical Development Process: Estimates of Development Costs and Times and the Effects of Proposed Regulatory Changes,” in Issues in Pharmaceutical Economics, ed. Robert I. Chien, 151-187. Boston: Lexington Books
188. Hart, Oliver D., Andrei Shleifer, and Robert W. Vishny. 1997. “The Proper Scope of Government: Theory and an Application to Prisons.” Quarterly Journal of Economics112(4):1126-1161
189. Hassett, Kevin, and R. Glenn Hubbard. 1996. “Tax Policy and Investment.” Unpublished paper, Federai Reserve Board of Governors and Columbia University Business School
190. Heffler, Stephen, Sheila Smith, Sean Keehan, Christine Borger, M. Kent Clemens, and Christopher Truffer. 2005. “U.S. Health Spending for 2004-2014.” Health Affairs - Web Exclusive W5:74-85
191. Henderson, Rebecca, and Iain Cockburn. 1996. “Scale, Scope and Spillovers: The Deter- minants of Research Productivity in Drug Discovery.” RAND Journal of Economics27(1):32-59
192. Hill, S. R., A. S. Mitchell, and D. A. Henry. 2000. “Problems with the Interpretation of Pharmacoeconomic Analyses: A Review of Submissions to the Australian Pharmaceutical Benefits Scheme.” Journal of the American Medical Association 283:2116-2121
193. Hinman, A. 2004. “Institute of Medicine Report on Financing Vaccines in the 21st Century: National Vaccine Advisory Committee/National Vaccine Program Office Response.” Available at www.hhs.gov/nvpo/nvac/NVAC-IOM100604.htm
194. Hinman, A. 2005. “Addressing the Vaccine Financing Conundrum.” Health Affairs24(3):701-704
195. Hoek, Janet, Philip Gendall, and John Calfee. 2004. “Direct-to-Consumer Advertising of Prescription Medicines in the United States and New Zealand: An Analysis of Regulatory ApproachesandConsumerResponses.” International JournalofAdvertising23:197-227
196. Hollis, A. 2005a. “An Efficient Reward System for Pharmaceutical Innovation.” Preprint. Available at http://econ.ucalgary.ca/fac-files/ah/drugprizes.pdf#search=’hollis%20and%20an%20efficient%20reward%20system
197. Hollis, A. 2005b. “An Optional Reward System for Neglected Disease Drugs.” Mimeo, University of Calgary
198. Hollon, Matthew F. 1999. “Direct-to-ConsumerPrescription Drugs: Creating Consumer Demand.” Journal ofthe American Medical Association 281(4):382–384
199. Holmstrom, Bengt, and Jean Tirole. 1993. “Market Liquidity and Performance Monitoring.” Journal ofPolitical Economy 101:678–709
200. Hotz, J., A. Ahituv, and T. Philipson. 1996. “The Responsiveness of the Demand for Condoms to the Local Prevalence of AIDS.” Journal of Human Resources 21(4):869–897
201. Hsieh, Chee-Ruey, and Frank A. Sloan. 2006. “Adoption of Pharmaceutical Innovation and the Growth of Drug Expenditure: The Taiwanese Experience.” Working Paper, Duke University
202. Hsu, J. C., and E. S. Schwartz. 2003. “A Model of R&D Valuation and the Design of Research Incentives.” National Bureau of Economic Research Working Paper 10041
203. Hubbard, R. G., J. Skinner, and S. P. Zeldes. 1995. “Precautionary Saving and Social Insurance.” Journal ofPolitical Economy 103:360–399
204. Hudson, John. 2000. “Generic Take-Up in the Pharmaceutical Market Following Patent Expiry: A Multi-Country Study.” International Review of Law and Economics 20:205–221
205. Hume, C., and W. Schmitt. 2001. “Pharma’s Prescription.” Chemical Week, Aprii 11,21
206. Hurwitz, Mark A., and Richard E. Caves. 1988. “Persuasion or Information? Promotion and the Shares of Brand Name and Generic Pharmaceuticals.” Journal of Law and Economics 31, no. 5:299–320
207. Huskamp, H. A., M. B. Rosenthal, R. G. Frank, and J. P. Newhouse. 2000. “The Medicare Prescription Drug Benefit: HowWillthe Game Be Played?” Health Affairs 19(2):8–23
208. Iglehart, John K., ed. 2004. “Variations Revisited: ASupplementto Health Affairs.” Health Affairs - Web Exclusive 23:3–4
209. Iizuka, Toshi. 2004. “What Explains the Use of Direct-to-Consumer Advertising of Prescription Drugs?” Journal ofIndustrial Economics 52(3):349–379
210. Iizuka, Toshi, and Ginger Z. Jin. 2003. “The Effects of Direct-to-Consumer Advertising in the Prescription Drug Markets.” Unpublished working paper, Vanderbilt University, Owen Graduate School of Management, September 29
211. Iizuka, Toshi, and Ginger Z. Jin. 2005a. “The Effect of Prescription Drug Advertising on Doctor Visits.” Journal ofEconomics and Management Strategy, forthcoming
212. Iizuka, Toshi, and Ginger Z. Jin. 2005b. “Direct to Consumer Advertising and Pre- scription Choice.” Working paper, Vanderbilt University, Owen Graduate School of Management
213. IMS. 2004. Global Pharmaceutical Review. October. London
214. IMS Intelligence. 2005. Chart 1. Power Point Presentation Supplied via e-mail by Raymond Hill of IMS, May 21
215. Institute of Medicine. 2000. Callingthe Shots: Immunization Finance Policies andPractices. Washington, DC: National Academies Press
216. Institute of Medicine. 2003. Hidden Costs, ValueLost: Uninsurance in America. Washington, DC: National Academies Press, 2003
217. Institute of Medicine. 2004. Financing Vaccines in the 21st Century: Assuring Access and Availability. Washington, DC: National Academies Press
218. Institute of Medicine, J. Corrigan, A. Greiner, and S. M. Erickson. 2002. Fostering Rapid Advances in Health Care: Learning from System Demonstrations. Washington, DC: National Academies Press
219. Ives, D., J. Lave, N. Traven, and L. Kuller. 1994. “Impact of Medicare Reimbursement on Influenza Vaccination Rates in the Elderly.” Preventive Medicine 23:134-141
220. Jensen, Elizabeth J. 1987. “Research Expenditures and the Discovery of New Drugs.” Journal of Industrial Economics 36:83-95
221. Jensen, G. A., and M. A. Morrisey. 1999. “Employer-Sponsored Health Insurance and Mandated Benefit Laws.” Milbank Quarterly 77(4):425-459
222. Jewkes, John, David Sawyers, and Richard Stillerman. 1958. The Sources of Invention. London: Macmillan
223. Jones, Charles. 1998. Introduction to Economic Growth. New York: W. W. Norton
224. Joskow, P. L. 1989. “Regulatory Failure, Regulatory Reform, and Structural-Change in the Electrical-Power Industry.” Brookings Papers on EconomicActivity (1998):125-208
225. Juhl, R. P. 2000. “Prescription to Over-the-Counter Switch: A Regulatory Perspective.” Clinical Therapeutics 20(Supp. C):111-117
226. Kahn, A. 1971. The Economics of Regulation: Principles and Institutions. New York: Wiley
227. Kaiser Family Foundation. 2001. Prescription Drug Trends: A Chartbook UpdateWashington, DC
228. Kaiser Family Foundation. 2002. Employer Health Benefits: 2002 Annual Survey. Washington, DC
229. Kaiser Family Foundation. 2005. Prescription Drug Coverage for Medicare Beneficiaries: A Summary of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Available atwww.kff.org/medicare/6112.cfm. Last accessed November 5, 2005
230. Kanavos, Panos, and Uwe E. Reinhardt. 2003. “Reference Pricing For Drugs: Is It Com- patible with U.S. Health Care?” Health Affairs 22(3):16-30
231. Kettler, Hannah E. 1999. “Updating the Cost of a New Chemical Entity.” London: Office ofHealth Economics
232. Keynes, John Maynard. 1936. The General Theory of Employment, Interest, and Money. London: Macmillan
233. Kim, Jong-Il, and Lawrence J. Lau. 1994. “The Sources of Economic Growth of the East Asian Newly Industrialized Countries.” Journal ofthe Japanese and International Economies 8:235-271
234. Kitch, E. W. 1977. “The Nature and Function of the Patent System.” Journal ofLaw and Economics 10:265-290
235. Klein, Daniel B. 2005. “Policy Medicine versus Policy Quackery: Economists against the FDA.” Knowledge, Technology, and Policy 31(1):92-101
236. Klick, J., and Sara Markowitz. 2003. “Are Mental Health Insurance Mandates Effective? Evidence from Suicides.” National Bureau of Economic Research Working Paper 9994
237. Kobelt, G., L. Jönsson, A. Young, and K. Eberhardt. 2003. “The Cost-Effectiveness of Infliximab (Remicade) in the Treatment of Rheumatoid Arthritis in Sweden and the United Kingdom Based on the ATTRACT Study.” Rheumatology 42:326-335
238. Kravitz, Richard I., Ronald M. Epstein, Mitchell D. Feldman, Carol E. Franz, Rahman Azari, Michael S. Wilkes, Ladson Hinton, and Peter Franks. 2005. “Influence of Patients’ Requests for Direct-to-Consumer Advertised Antidepressants: A Random- ized ControlledTrial.” Journal ofthe American Medical Association 293(16):1995-2002
239. Kreling, D. H., T. Collins, H. Lipton, and K.C. Hertz. 1996. “Assessing the Impact of Pharmacy Benefit Managers.” HCFA Contract Report, HCFA 95-023/PW, Septem- ber 30
240. Kremer, M. 1998. “Patent Buyouts: A Mechanism for Encouraging Innovation.” Quar- terly Journal of Economics 113(4):1137-1167
241. Kremer, M. 2000a. “Creating Markets for New Vaccines Part I: Rationale.” National Bureau of Economic Research Working Paper 7716
242. Kremer, M. 2000b. “Creating Markets for New Vaccines Part II: Design Issues.” National Bureau of Economic Research Working Paper 7717
243. Kremer, M., and R. Glennerster. 2004. Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases. Princeton, NJ: Princeton University Press
244. Kremer, M., and C. M. Snyder. 2003. “Why Are Drugs More Profitable than Vaccines?” National Bureau of Economic Research Working Paper 9833
245. Kronick, R., and T. Gilmer. 2002. “Insuring Low-Income Adults: Does Public Coverage CrowdOut Private?” Health Affairs 21(1):225-239
246. Laffont, J.-J., and J. Tirole. 1993. A Theory of Incentives in Procurement and Regulation. Cambridge, MA: MIT Press
247. Landau, Ralph, et al. 1999. Pharmaceutical Innovation: RevolutionizingHuman Health. Philadelphia: Chemical Heritage Press
248. Lanjouw, J. 2004. “Outline of Foreign Filing License Approach.” Washington, DC: Center for Global Development & Global Health Policy Research Network. Available at www.cgdev.org/docs/FFLOutline.pdf
249. Lanjouw, J. O., and M. MacLeod. 2005. “Statistical Trends in Pharmaceutical Research for PoorCountries.” Available at www.who.int/intellectualproperty/studies. Last accessed May 10, 2005
250. Learner, Josh, and Robert P. Merges. 1998. “The Control of Technology Alliances: An Empirical Analysis of the Biotechnology Industry.” Journal of Industrial Economics46:125-156
251. Learner, Josh, and Alexander Tsai. 2000. “Do Equity Financing Cycles Matter? Evidence from Biotechnology Alliances.” National Bureau of Economic Research Working Paper W7464
252. Leffler, Keith B. 1981. “Promotion or Information? The Economics ofPrescription Drug Advertising.” Journal ofLaw and Economics 24(2):45-74
253. Levin, Richard C., Alvin K. Klevorick, Richard R. Nelson, and Sidney G. Winter. 1987. “Appropriating the Returns from Industrial Research and Development.” Brookings Papers on Economic Activity 3:783-820
254. Lichtenberg, Frank R. 1984. “The Relationship between Federai Contract R&D and Company R&D.” American Economic Review 74(2):73-78
255. Lichtenberg, Frank R. 1986. “Energy Prices and Induced Innovation.” Research Policy15:67-75
256. Lichtenberg, Frank R. 1987. “Changing Market Opportunities and the Structure of R&D Investment: The Case of Energy.” Energy Economics 9(3):154-158
257. Lichtenberg, Frank R. 1988. “The Private R&D Investment Response to Federal Design and Technical Competitions.” American Economic Review 78(3):550-559
258. Lichtenberg, Frank R. 1996. “The Effect of Pharmaceutical Utilization and Innovation on Hospitalization and Mortality.” National Bureau of Economic Research Working Paper 5418
259. Lichtenberg, Frank R. 2001a. “The Allocation of Publicly Funded Biomedicai Research,” in Medical Care Output and Productivity, Studies in Income and Wealth vol. 62, ed. by Ernst Berndt and David Cutler, 565-589. Chicago: University of Chicago Press
260. Lichtenberg, Frank R. 2001b. “The Effect of New Drugs on Mortality from Rare Diseases and HIV.” National Bureau of Economic Research Working Paper 8677
261. Lichtenberg, Frank R. 2003a. “Pharmaceutical Innovation, Mortality Reduction, and Economic Growth.” In Measuring the Gains from Medical Research: An Economic Approach, ed. by Kevin M. Murphy and Robert H. Topel, 74–109. Chicago: University of Chicago Press
262. Lichtenberg, Frank R. 2003b. “The Effect of New Drugs on HIV Mortality in the U.S., 1987–1998.” Economics and Human Biology 1:259–266
263. Lichtenberg, Frank R. 2003c. “The Benefits to Society of New Drugs: A Survey of the Econometric Evidence.” Proceedings of the Federal Reserve Bank of Dallas(September):43–59
264. Lichtenberg, Frank R. 2004a. “Public Policy and Innovation in the U.S. Pharmaceutical Industry,” in Public Policy and the Economics of Entrepreneurship, ed. by Douglas Holtz-Eakin and Harvey S. Rosen, 83–113. Cambridge, MA: MIT Press
265. Lichtenberg, Frank R. 2004b. “Sources ofU.S. Longevity Increase, 1960–2001.” Quarterly Review ofEconomics and Finance 44(3):369–389
266. Lichtenberg, Frank R. 2005a. “Pharmaceutical Innovation and the Burden of Disease in Developedand Developing Countries.” Journal of Medicine and Philosophy 30(6):663–690
267. Lichtenberg, Frank R. 2005b. “The Impact of New Drug Launches on Longevity: Evidence from Longitudinal Disease-level Data from 52 Countries, 1982–2001.” International Journal of Health Care Finance and Economics 5(1):47–73
268. Lichtenberg, Frank R., and Suchin Virabhak. 2002. “Pharmaceutical Embodied Technical Progress, Longevity, and Quality of Life: Drugs as “Equipment for Your Health.” National Bureau of Economic Research Working Paper 9351
269. Lichtenberg, F., and J. Waldfogel. 2003. “Does Misery Love Company? Evidence from Pharmaceutical Markets before and after the Orphan Drug Act.” National Bureau of Economic Research Working Paper 9750
270. Light, Donald W., and Rebecca N. Warburton. 2005. “Extraordinary Claims Require Extraordinary Evidence.” Journal of Health Economics 24(5):1030–1033
271. Ling, Davina C., Ernst R. Berndt, and Margaret K. Kyle. 2002. “Deregulating Direct-to- Consumer Marketing of Prescription Drugs: Effects on Prescription and Over-the- Counter Product Sales.” Journal ofLaw and Economics 14:691–723
272. Livernois, J. R. 1988. “Estimates ofMarginal Discovery Costs for Oil and Gas.” Canadian Journal ofEconomics 21(2):379–393
273. López-Casasnovas, G., and B. Jönsson, eds. 2001. Reference Pricing and Pharmaceutical Policy. Barcelona: Springer Verlag Ibéria
274. López-Casasnovas, G., and J. Puig-Junoy. 2001. “Review of the Literature on Reference Pricing,” in Reference Pricing and Pharmaceutical Policy, ed. G. López-Casasnovas and B. Jönsson, 1–41. Barcelona: Springer Verlag Ibéria
275. Lo Sasso, A. T., and T. C. Buchmueller. 2004. “The Effect of the State Children’s Health Insurance Program on Health Insurance Coverage.” Journal of Health Economics23(5):1059–1082
276. Luman, E. T., L. E. Barker, K. M. Shaw, et al. 2005. “Timeliness ofChildhood Vaccinations in the United States: Days Undervaccinated and Number of Vaccines Delayed.” Journal ofthe American Medical Association 293(10):1204–1211
277. Lurie, N., W. G. Manning, C. Peterson, et al. 1987. “Preventive Care: Do We Practice What We Preach?” American Journal of Public Health 77:801–804
278. Mackenbach, J. P. 1991. “Health Care Expenditure and Mortality from Amenable Con- ditions in the European Community.” Health Policy 19:245-255
279. Manca, A., P. Lambert, S. Hahn, M. J. Sculpher, and N. Rice. 2004. “Exploring the Gen- eralisability by Location of Multilevel Trial-Based CEA Results: The Case of Bayesian Hierarchical Linear Modeling,” in 5th European Conference of Health Economics, 542. London: Open Mind Journals
280. Mansfield, Edwin. 1977. The Production and Application of New Industrial Technology. New York: W. W. Norton
281. Mansfield, Edwin. 1986. “Patents and Innovation: An Empirical Study.” Management Science 32(2):173-181
282. Masson, A., and R. Steiner. 1985. “Generic Substitution and Prescription Drug Prices: Economic Effects of State Drug Product Selection Laws.” Staff Report of the Bureau of Economics, FTC, Washington, DC, October
283. Maurer, S. 2005. “The Right Tool(s): Designing Cost-Effective Strategies for Neglected Disease Research.” Geneva: WHO Commission on Intellectual Property Rights, Innovation, and Public Health. Available at www.who.int/intellectualproperty/studies/research_development/en/
284. Maurer, S., A. Rai, and A. Sali. 2004. “Finding Cures For Tropical Diseases: Is Open Source an Answer?” PLOS: Medicine 1:183-186. Available at http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0010056
285. Maurer, S., and S. Scotchmer. 2004. “Procuring Knowledge,” in Advances in the Study of Entrepreneurship, Innovation and Growth, ed. by G. Libecap, 15:1-31. Greenwich, CT: JAI Press
286. McCarran, E. 1991. “Rxto OTC Switches: Promises and Pitfalls.” Medical Marketing and Media 13-26
287. McGuire, T. G. 2003. “Setting Prices for New Vaccines (in Advance).” International Journal of Health Care Finance and Economics 3(3):207-224
288. Megginson, William L., and Jeffry M. Netter. 2001. “From State to Market: A Survey of Empirical Studies on Privatization.” Journal of Economic Literature 39(2):321-389
289. Meltzer, M. I., N. J. Cox, and K. Fukuda. 1999. “The Economic Impact of Pandemic Influenza in the United States: Priorities for Intervention.” EmergingInfectious Disease5(5):659-671
290. Menzin J, G. Oster, L. Davies, M. F. Drummond, W. Greiner, C. Lucioni, J. L. Merot, F. Rossi, V. D. Schulenberg, and E. Souetre. 1996. “A Multinational Economic Evaluation of rhDNase in the Treatment of Cystic Fibrosis.” International Journal of Technology Assessment in Health Care 12(1):52-61
291. Merrill, S. A., R. C. Levin, and M. B. Myers. 2004. A Patent System for the 21st Century. Washington, DC: National Academies Press
292. Millenson, Michael L. 2004. “Getting Doctors to Say Yes to Drugs: The Cost and Quality Impact of Drug Company Marketing to Physicians.” Chicago: Blue Cross Blue Shield Association. Available at www.bcbs.com/coststudies/reports/Drug_Co_Marketing_Report.pdf. Last accessed November 20, 2005
293. Miller, Richard D., Jr., and H. E. Frech III. 2004. Health Care Matters: Pharmaceuticals, Obesity, and the Quality of Life. Washington, DC: AEI Press
294. Mitchell, V. S., N. M. Philipose, and J. P. Sanford, eds. 1993. The Childrens Vaccine Initiative: Achieving the Vision. Washington, DC: National Academy Press
295. Morgan, Steven G. 2002. “Quantifying Components of Drug Expenditure Inflation: The British Columbia Seniors’ Drug Benefit Plan.” Health Services Research 37:1243-1266
296. Mueller, D. 1986. The Persistence ofProfits. Cambridge: Cambridge University Press
297. Murphy, Kevin, and Robert H. Topel. 2003a. “The Economic Value of Medicai Research,” in Measuring the Gains from Medical Research: An Economic Approach, ed. by Kevin M. Murphy and Robert H. Topel, 41-73. Chicago: University of Chicago Press
298. Murphy, Kevin M., and Robert H. Topel. 2003b. Measuring the Gains from Medical Research: An Economic Approach. Chicago, IL: University of Chicago Press
299. Murphy, Kevin M., and Robert H. Topel. 2005. “The Value of Health and Longevity.” University of Chicago Working Paper
300. Myers, Stewart. 1999. “Measuring Pharmaceutical Risk and the Cost of Capital,” in Risk and Return in the Pharmaceutical Industry, ed. by Jon Sussex and Nick Marchant, 59-76. London: Office ofHealth Economics
301. Nace, N., C. Larson, T. Lester, and J. Kosinski. 1999. “Perceived Barriers to Childhood Immunization: A Physician and Parent Survey in a Southeastern Urban/Rural Community.” Tennessee Medicine 92(7):265-268
302. National Association of Boards of Pharmacy. 2004. Survey of Pharmacy Law for 20032004. Park Ridge, IL: NABC
303. National Institute for Clinical Excellence (NICE). 2000. “Guidance on the Use of Zanamivir (Relenza) in the Treatment of Influenza.” Technology Appraisal Guidance No. 15. London: NICE
304. National Institute for Clinical Excellence (NICE). 2004. Guide to the Methods of Technology Appraisal. London: NICE
305. National Science Council (Taiwan). 2004. Indicators of Science and Technology. Taipei: NSC
306. National Science Foundation. 2006. “National Expenditures for R&D, from Funding Sectors to Performing Sectors.” Available at www.nsf.gov/sbe/srs/nsf03313/tables/tab1b.xls
307. Nelson, Philip K. 1970. “Information and Consumer Behavior.” Journal of Political Economy 78(2):311–329
308. Nelson, Philip K. 1974. “Advertising as Information.” Journal of Political Economy82(4):729-754
309. Neslin, Scott A. 2001. ROIAnalysis of Pharmaceutical Promotion (RAPPP). Unpublished study, Hanover, NH, Amos Tuck School ofBusiness, Dartmouth College. Available at www.rxpromoroi.org/rapp
310. Neumann, P. J. 2004. “Why Don’t Americans Use Cost-Effectiveness Analysis?” American Journal ofManaged Care 10:308-312
311. Newhouse, Joseph P. 2004. “How Much Should Medicare Pay for Drugs?” Health Affairs23(1):89-102
312. New Zealand Ministry of Health. 2000a. “Direct to Consumer Advertising of Prescription Medicines under Review.” Media release, December 1. Available at www.moh.govt.nz/moh.nsf. Last accessed April 30, 2005
313. New Zealand Ministry of Health. 2000b. “Direct-to-Consumer Advertising of Prescription Medicines in New Zealand: A Discussion Paper.” November. Available as dtcaDiscussionDoc.pdf at www.moh.govt.nz/moh.nsf. Last accessed April 30, 2005
314. Nexoe, J., J. Kragstrup, and T. Ronne. 1997. “Impact of Postal Invitations and User Fee on Influenza Vaccination Rates among the Elderly: A Randomized Controlled Trial in General Practice.” Scandinavian Journal ofPrimary Health Care 15(2):109–112
315. Nicholson, S., Patricia M. Danzon, and Geoffrey McCullough. 2002. “Biotech- Pharmaceutical Alliances as a Signal of Asset and Firm Quality.” National Bureau of Economic Research Working Paper 9007
316. Nordhaus, William D. 2003. “The Health of Nations: The Contribution of Improved Health to Living Standards,” in Measuring the Gains from Medical Research: An Economic Approach,” ed. by Kevin M. Murphy and Robert H. Topel, 9–40. Chicago: University of Chicago Press
317. Oeppen, J., and J. W. Vaupel. 2002. “Demography: Broken Limits to Life Expectancy.” Science 296(5570):1029–1031
318. Offit, P. A. 2005. “WhyAre Pharmaceutical Companies Gradually Abandoning Vaccines?” Health Affairs 24(3):622–30
319. Ohmit, S. E., A. Furumotodawson, A. S. Monto, andN. Fasano. 1995. “Influenza Vaccine Use among an Elderly Population in a Community Intervention.” American Journal of Preventive Medicine 11(4):271–276
320. Or, Zeynep. 2003. “Determinants of Health Outcomes in Industrialised Countries: A Pooled, Cross-Country, Time-Series Analysis.” OECD Economic Studies No. 30, 2000/I. Available at www.oecd.org
321. Organization for Economic Cooperation and Development. 2004. “Table 1. Life Expectancy in Years,” in OECD Health Data 2004, 3rd ed. Available at www.oecd.org
322. Outterson, Kevin. 2004. “The U.S.-Australian Free Trade Agreement’s Unfortunate Attack and Good Healthcare Policy.” Comments Submitted to the U.S. Congress, House of Representatives, Committee on Ways and Means, June 22, 2004. Available at www.ita.doc.gov/td/chemicals/phRMA/Outterson%20Response1.pdf. Last accessed October 20, 2005
323. Padden, Michael, and Thomas Jenkins. 2004. “Hatch-Waxman Changes.” National Law Journal, February 23, p. 13
324. Palda, Kristian. 1969. Economic Analysis for Marketing Decisions. New York: Prentice- Hall
325. Palmer, S., M. Sculpher, M. Robinson Philips, L. Ginnelly, and D. Gary. 2005. “Management of Non-ST-Elevation Acute Coronary Syndromes: How Cost-Effective Are Glycoprotein IIb/IIIa Antagonists in the UK National Health Service?” International Journal of Cardiology 100(2):229–240
326. Pauly, M. V.1998. Health Benefits at Work: An Economic and Political Analysis of Employment-Based Health Insurance. Ann Arbor: University of Michigan Press
327. Pauly, M. V. 2005. “Improving Vaccine Supply And Development: Who Needs What?” Health Affairs 24(3):680–689
328. Pauly, M. V., P. Danzon, P. Feldstein, and J. Hoff. 1991. “A Plan for ‘Responsible National Health Insurance.’” Health Affairs 10(1):5–25
329. Pharmaceutical R&D Policy Project. 2005. “The New Landscape of Neglected Disease Drug Development.” London: London School of Economics. Available at www.lse.ac.uk/collections/pressAndInformationOffice/PDF/Neglected_Diseases_05.pdf
330. Pharmaceutical Research and Manufacturers of America. 2000. Pharmaceutical Industry Profile. Washington, DC: Pharmaceutical Research and Manufacturing Association
331. Pharmaceutical Research and Manufacturers of America. 2005. PhRMA Guiding Prin- ciples: Direct to Consumer Advertisements about Prescription Medicines. Washington, DC, August 2005. Available at www.phrma.org
332. Philipson, T. 2000. “Economic Epidemiology and Infectious Diseases,” in Handbook of Health Economics, ed. by A. J. Culyer and J. P. Newhouse, 1B: 1761-1769. Amsterdam: Elsevier Science
333. Pines, Wayne L. 1999. “A History and Perspective on Direct-to-Consumer Promotion.” Food and DrugLaw Journal 54:489-518
334. Pleis, J., and J. Gentleman. 2002. “Using the National Health Interview Survey: Time Trends in Influenza Vaccinations among Targeted Adults.” Effective Clinical Practices5(3 Suppl.):E3
335. Plotkin, S. A. 2005. “Why Certain Vaccines Have Been Delayed or Not Developed at All.” Health Affairs 24(3):631-634
336. Pogge, T. 2005. “Human Rights and Global Health: A Research Program.” Metaphilosophy36(1/2):182-209
337. Poikoilainen, K., and J. Eskola. 1988. “Health Services Resources and Their Relation to Mortality from Causes Amenable to Health Care Intervention: A Cross-national Study.” International Journal of Epidemiology 17(1):86-89
338. Pomerantz, Jay M., Stan N. Finkelstein, Ernst R. Berndt, Amy W. Poret, Leon E. Walker, Robert C. Alber, Vidya Kadiyam, Mitali Das, David T. Boss, and Thomas H. Ebert. 2004. “Prescriber Intent, Off-Label Usage, and Early Discontinuation of Antidepres- sants.” Journal of Clinical Psychiatry 65(3):395-404
339. Popp, David. 2001. “Induced Innovation and Energy Prices.” National Bureau of Economic Research Working Paper 8284
340. Poulson, David, and Sarah Kellogg. “Private Labs’ Ability to Deliver Vaccines Ques- tioned.” Available at www.newhouse.com/archive/story1c110501.html
341. Rappuoli, Rino, Henry I. Miller, and Stanley Falkow. 2002. “The Intangible Value of Vaccination.” Science 297(5583):937-938
342. Rawlins, M. D., and A. J. Culyer. 2004. “National Institute for Clinical Excellence and Its Value Judgments.” British Medical Journal 329:224-227
343. Reichert, T. A., N. Sugaya, D. S. Fedson, et al. 2001. “The Japanese Experience with Vaccinating Schoolchildren against Influenza.” New England Journal of Medicine344(12):889-896
344. Reiffen, David, and Michael R. Ward. 2005. “Generic Drug Industry Dynamics.” Review of Economics and Statistics 87(1):37-49
345. Reiffen, David, and Michael Ward. 2006. “Branded Generics as a Strategy to Limit Cannibalization of Pharmaceutical Markets.” Managerial and Decision Economics, forthcoming
346. Reinhardt, UweE. 1996. “Rationingin Health Care: What It Is, What It Is Not, and Why We Cannot Avoid It,” in Strategic Choicesfor a Changing Health System, ed. by Stuart Altman and E. Uwe, 63-100. Chicago: Health Administration Press
347. Reinhardt, Uwe E. 1997. “Making Economic Evaluations More Respectable.” Social Science and Medicine 45(4):555-562
348. Reinhardt, Uwe E. 2001. “Can Efficiency in Health Care Be Left to the Market?” Journal of Health Politics, Policy and Law 26(5):967-992
349. Reinhardt, Uwe E. 2004. “An Information Infrastructure for the Pharmaceutical Market.” Health Affairs 23(1):107-112
350. Rice, Thomas H. 2002. The Economics ofHealth Reconsidered. Chicago: Health Admin- istration Press
351. Ridley, R. G. 2004. “Product Development Public-Private Partnerships for Diseases of Poverty,” in Combating Diseases Associated with Poverty, ed. by R. Widdus and K. White. Geneva: Initiative on Public-Private Partnerships for Health
352. Riordan, M. H., and D. E. M. Sappington. 1989. “Second Sourcing.” Rand Journal of Economics 20(1):41–58
353. ROC Department of Health. 2005. Health and Vital Statistical. Taipei: Department of Health
354. Rodewald, L., E. Maes, J. Stevenson, et al. 1999. “Immunization Performance Measure- ment in a Changing Immunization Environment.” Pediatrics 103(4):889-897
355. Rogerson, W. P. 1989. “Profit Regulation of Defense Contractors and Prizes for Innovation.” Journal of Political Economy 97(6):1284-1305
356. Rogerson, W. P. 1994. “Economic Incentives and the Defense Procurement Process.” Journal of Economic Perspectives 8(4):65-90
357. Romer, Paul. 1990. “Endogenous Technological Change.” Journal of Political Economy98:71-102
358. Rosenthal, Meredith B., Ernst R. Berndt, Julie M. Donohue, Arnold M. Epstein, and Richard G. Frank. 2003. “Demand Effects of Recent Changes in Prescription Drug Promotion,” chapter 1 in Frontiers in Health Policy Research, vol. 6, ed. Alan M. Garber, 1-26. Cambridge, MA: MIT Press for the National Bureau of Economic Research
359. Rosenthal, Meredith B., Ernst R. Berndt, Julie M. Donohue, Richard G. Frank, and Arnold M. Epstein. 2002. “Promotion of Prescription Drugs to Consumers.” New England Journal of Medicine 346(7):498-505
360. Rosso, R. 2001. “Trends in Food Stamp Program Participation Rates: 1994 to 1999.” Alexandria, VA: United States Department ofAgriculture, Food and Nutrition Service
361. Rubin, Robert, Ann Hawk, and Elisa Cascade. 1998. “PBMs: A Purchaser’s Perspective,” in PBMs: Reshaping the Pharmaceutical Distribution Network, ed. by Sheila Shulman, Elaine Healy, and Louis Lasagna, 30. Binghamton, NY: Pharmaceutical Products Press
362. Saha, Atanu, Henry Grabowski, Howard Birnbaum, Paul Greenberg, and Oded Bizan. “Generic Competition in the U.S. Pharmaceutical Industry.” International Journal of the Economics of Business 13(1):15–38
363. Salkever, D., and R. Frank. 1996. “Economic Issues in Vaccine Purchase Agreements,” in Supplying Vaccine: An Economic Analysis of Critical Issues, ed. by M. Pauly, C. A. Robinson, S. Sepe, M. Sing, and M. K. Willian. Amsterdam: IOS Press
364. Satterthwaite, P. 1997. “A Randomised Intervention Study to Examine the Effect on Immunisation Coverage of Making Influenza Vaccine Available at No Cost.” New Zealand Medical Journal 110(1038):58-60
365. Saunders, Barrie. 2003. “Direct to Consumer Advertising of Prescription Drugs in New Zealand: Professore’ Protest to Government Placed under the Microscope.” Wellington, New Zealand: Saunders Unsworth. Available at www.sul.co.nz
366. Scharfstein, D. 1988. “The Disciplinary Role of Takeovers.” Review of Economic Studies55(2):185-199
367. Scherer, F. M. 2000. “The Pharmaceutical Industry,” in Handbook of Health Economics, vol. 1, ed. by A. J. Culyer and J. P. Newhouse, 297-336. Amsterdam: Elsevier Science
368. Scherer, F. M. 2001. “The Link between Gross Profitability and Pharmaceutical R&D Spending.” Health Affairs 20:216-220
369. Scherer, F. M., and D. R. Ross. 1990. Industrial Market Structure and Economic Performance. 3rded. Boston: Houghton-Mifflin
370. Schmalensee, R. 1979. The Control of National Monopolies. Lexington, MA: D. C. Heath, Lexington Books
371. Schmookler, Jacob. 1966. Invention and Economic Growth. Cambridge, MA: Harvard University Press
372. Schwartzman, David, and Antonio Cognato. 1996. “Has Pharmaceutical Research Become More Scientific?” Review of Industrial Organization 11:841–851
373. Schweitzer, Stuart. 1997. Pharmaceuticals, Economics, and Policy. New York: Oxford University Press
374. Scotchmer, S. 2004. Innovation and Incentives. Cambridge, MA: MIT Press
375. Scott Morton, F. M. 1999. “Entry Decisions in the Generic Pharmaceutical Industry.” RAND Journal ofEconomics 30(3):421–440
376. Scott Morton, F. M. 2000. “Barriers to Entry Brand Advertising, and Generic Entry in the U.S. Pharmaceutical Industry.” International Journal of Industrial Organization18(7):1085–1104
377. Scriabiane, Alexander. 1999. “The Role of Biotechnology in Drug Development,” in Pharmaceutical Innovation: Revolutionizing Human Health, ed. by Ralph Landau, Basii Achilladelis, and Alexander Scriabine. Philadelphia: Chemical Heritage Foundation Press
378. Sculpher, M. J., F. S. Pang, A. Manca, M. F. Drummond, S. Golder, H. Urdahl, L. M. Davies, and A. Eastwood. 2004. Generalisability in Economic Evaluation Studies in Health Care: A Review and Case Studies. Health Technology Assessment 8(49) (whole issue)
379. Shavell, S., and T. Van Ypersele. 2001. “Rewards versus Intellectual Property Rights.” Journal ofLaw and Economics 44(2):525–547
380. Shaw, James W., William C. Horrace, and Ronald J. Vogel. 2005. “The Determinants of Life Expectancy: An Analysis of the OECD Health Data.” Southern Economic Journal71(4):768–783
381. Shleifer, Andrei. 1998. “State versus Private Ownership.” Journal of Economic Perspectives12(4):133–150
382. Shleifer, A., and R. Vishny. 1994. “Politicians and Firms.” QuarterlyJournal of Economics109:995–1025
383. Siegel, Jonathan B. 2004. “Financial Aspects of 180-Day Generic Exclusivity.” Presentation to the Food and Drug Law Institute Conference on Two Decades of Hatch- Waxman, December 1–2, Washington, DC
384. Sinclair, G., S. Klepper, and W. Cohen. 2000. “What’s Experience Got to Do with It? Sources of Cost Reduction in a Large Specialty Chemicals Producer.” Management Science 46(1):25–28
385. Skinner, J., and J. E. Wennberg. 2000. “How Much Is Enough? Efficiency and Medicare Spending in the Last Six Months of Life,” in The ChangingHospital Industry: Compar- ing Not-for-Profit and For-Profit Institutions, ed. by David Cutler, 169–193. Chicago: University of Chicago Press
386. Sloan, Frank A., and Chris J. Conover. 1998. “Effects ofState Reforms on Health Insurance Coverage of Adults.” Inquiry 35:280–293
387. Sloan, Frank A., and Henry G. Grabowski. 1997. “Introduction and Overview.” Social Science and Medicine 54(4):505–510
388. Sloan, Frank A., K. Whetten-Goldstein, and A. Wilson. 1997. “Hospital Pharmacy Deci- sions, Cost Containment, and the Use of Cost-Effectiveness Analysis.” Social Science and Medicine 54(4):525-536
389. Smith, J. S. 1990. Patentingthe Sun. New York: Morrow
390. Song, F., D. G. Altman, A. M. Glenny, and J. Deeks. 2003. “Validity of Indirect Comparison for Estimating Efficacy of Competing Interventions: Empirical Evidence from Published Meta-Analyses.” British Medical Journal 326:472-478
391. Sorenson, Alan T. 2000. “Equilibrium Price Dispersion in Retail Markets for Prescription Drugs.” Journal ofPolitical Economy 108(4):833-850
392. Spence, M. 1984. “Cost Reduction, Competition, and Industry Performance.” Econometrica 52:101-121
393. Spulber, D. 1989. Regulation and Markets. Cambridge, MA: MIT Press
394. Stapleton, S. 2004. “Project BioShield.” American Medical News 47(31):19
395. Statistics Canada. 1974. Life Tables, Canada and Provinces, 1970–1972. Ottawa: Minister of Industry
396. Statistics Canada. 2002. Life Tables, Canada, Provincesand Territories, 1995–1997. Ottawa: Minister of Industry
397. Stein, J. C. 1988. “Takeover Threats and Managerial Myopia.” Journal ofPolitical Economy96(1):61-80
398. Stern, Scott, Michael E. Porter, and Jeffrey L. Furman. 2000. “The Determinants of National Innovative Capacity.” National Bureau of Economics Research Working Paper 7876
399. Stinnett, A. A., et al. 1996. “The Cost Effectiveness of Dietary and Pharmacologic Therapy for Cholesterol Reduction in Adults,” in Cost Effectiveness in Health and Medicine, ed. by M. Gold, J. E. Siegel, L. B. Russell, and M. C. Weinstein, 349-391. Oxford: Oxford University Press
400. Stratton, K. R., J. S. Durch, and R. S. Lawrence. 2000. Vaccines for the 21st Century: A Tool for Decision-Making. Washington, DC: Institute of Medicine, National Academy Press
401. Summers, L. H. 1989. “What Can Economics Contribute to Social Policy?” American Economic Review 79(2):177-183
402. Tan, Litjen, and the American Medicai Association. 2006. “Strengthening the Supply of Routinely Recommended Vaccines in the United States: A Perspective from the American Medicai Association.” Clinical Infectious Diseases 42(Suppl. 3):S121-S124
403. Taylor, C. R. 1995. “Digging for Golden Carrots: An Analysis of Research Tournaments.” American Economic Review 85(4):872-890
404. Temin, Peter. 1980. Taking Your Medicine: Drug Regulation in the United States. Cambridge, MA: Harvard University Press
405. Thomas, P. 2002. “The Economics of Vaccines.” Harvard Medical International (HMI) World, September/October
406. Tobin, James. 1969. “A General Equilibrium Approach to Monetary Theory.” Journal of Money, Credit, and Banking 1(1):15-29
407. Toop, Les, Dee Richards, Tony Dowell, Murray Tilyard, Tony Fraser, and Bruce Arrol. 2003. “Direct to Consumer Advertising of Prescription Drugs in New Zealand: For Health or for Profit?” Report to the Minister of Health Supporting the Case for a Ban on DTCA, February. Available at www.chmeds.ac.nz/report.pdf. Last accessed April 30, 2005
408. Towse, A. 2004. “Developing the Idea of Transferable Intellectual Property Rights (TIPP) to Incentivize R&D in Drugs and Vaccines for Neglected Diseases.” Office of Health Economics, London, March 2, Appendix I, 22–24
409. Towse, A., and H. Kettler. 2005. “Review of IP and Non-IP Incentives for R&D for Diseases of Poverty: What Type of Innovation Is Required and How Can We Incentivise the Private Sector to Deliver It?” Available at www.who.int/intellectualproperty/studies/health_innovation/en. Last accessed May 10, 2005
410. Towse A., J. Mestre-Fernandez, andO. Renowden. 2004. “Estimates of the Medium Term Financial Resource Needs for Development of Pharmaceuticals to Combat ‘Neglected Diseases,’” in Combating Diseases Associated with Poverty, ed. by R. Widdus and K. White. Geneva: Initiative on Public-Private Partnerships for Health
411. Tufts Center for the Study of Drug Development. 2003. “Total Cost to Develop a New Prescription Drug, Including Cost of Post-Approval Research, Is $897 million.” Press release, May 13, 2003. Available at www.csdd.tufts.edu
412. Turner, Margaret A. 2003. “Strengths and Weaknesses ofthe Housing Voucher Program.” Congressional Testimony prepared for the Committee on Financial Services, Subcom- mittee on Housing and Community Opportunity, U.S. House of Representatives, June 17, 2003. Available at www.urban.org/url.cfm?ID=900635
413. U.S. Centers for Disease Control and Prevention. 1999. “An Ounce of Prevention… What Are the Returns?” 2nd ed. Available at www.cdc.gov/epo/prevent.htm
414. U.S. Centers for Disease Control and Prevention. 2002a. “Influenza and Pneumococcal Vaccination Levels among Persons Aged >65 years, United States, 2001.” Morbidity and Mortality Weekly Report 51(45):1019-1024
415. U.S. Centers for Disease Control and Prevention. 2002b. “National, State, and Urban Area Vaccination Coverage Levels among Children Aged 19-35 Months: United States,” Morbidity and Mortality Weekly Report 3:664-666
416. U.S. Centers for Disease Control and Prevention. 2003. “National, State, and Urban Area Vaccination Coverage Levels among Children Aged 19-35 Months: United States,”Morbidity and Mortality Weekly Report52(31):728-732
417. U.S. Centers for Disease Control and Prevention. 2004. “Influenza Viruses.” Available at www.cdc.gov/flu/avian/gen-info/flu-viruses.htm. Last accessed March 2, 2005
418. U.S. Centers for Disease Control and Prevention. 2005a. “Influenza Pandemics.” Available at www.cdc.gov/flu/avian/gen-info/pandemics.htm. Last accessed March 2,2005
419. U.S. Centers for Disease Control and Prevention. 2005b. “Avian Influenza Infection in Humans.” Available at www.cdc.gov/flu/avian/gen-info/avian-flu-humans.htm. Last accessed March 2, 2005
420. U.S. Centers for Medicaid and Medicare Services. 2003. “The Nation’s Health Care Dollar: 2001.” Washington, DC: Government Printing Office
421. U.S. Committee on Ways and Means, U.S. House of Representatives. 2003. Background Material and Data on the Programs within the Jurisdiction ofthe Committee on Ways and Means. (Informally known as the “Green Book.”) WMCP 108-6. Washington, DC: Government Printing Office
422. U.S. Congressional Budget Office. 1998. “How Increased Competition Has Affected Prices and Returns in the Pharmaceutical Industry.” July, 38. Washington, DC: Government Printing Office
423. U.S. Department of Health and Human Services. 2002. “Payment by Results” Break- through Ends Years ofUncertainty for MS Patients: Agreement Follows Recommendation from NICE. Washington, DC: Government Printing Office
424. U.S. Department of Health and Human Services. 2004. “Pandemic Influenza Preparedness and Response Plan,” 1–54. Washington, DC: Government Printing Office
425. U.S. Food and Drug Administration. 1999. “Creating a Risk Management Framework: Report to the FDA Commissioner from the Task Force on Risk Management.” Washington, DC: Government Printing Office
426. U.S. Food and Drug Administration. 2005. “CDER NDAs Approved in Calen- dar Years 1990–2204 by Therapeutic Potential and Chemical Type.” Available at www.fda.gov/cder/rdmt/pstable.htm
427. U.S. Senate. 1960. Administered Prices in the Drug Industry. Hearings before the Sub-Committee on Antitrust and Monopoly, 86th Congress, 1959 and 1960, Part 18. Washington, DC: Government Printing Office
428. U.S. Senate, Republican Policy Committee. 2005. “Pharmaceutical Price Controls Abroad: An Unfair Trade Policy.” Available at www.kyl.senate.gov/legis_center/rpc_110603.pdf. Last accessed October 20, 2005
429. Vernon, John M. 1981. “Concentration, Promotion, and Market Share Stability in the Pharmaceutical Industry.” Journal of Industrial Economics 19(3):246–266
430. Vernon, J., and H. Grabowski. 2000. “The Distribution ofSales Revenues from Pharmaceutical Innovation.” Pharmo Economics 18(1):21–32
431. Vernon, John M., and Peter Gusen. 1974. “Technical Change and Firm Size: Pharmaceutical Industry.” Review of Economics and Statistics 56:294–302
432. Viscusi, W. Kip. 1993. “The Value of Risks to Life and Health.” Journal of Economic Literature 31:1912–1946
433. Viscusi, W. Kip. 1995. “Discounting Health Effects for Medical Decisions,” in Valuing Health Care, ed. Frank Sloan, 125–147. Cambridge: Cambridge University Press
434. Viscusi, W. Kip, and Joseph E. Aldy. 2003. “The Value of a Statistical Life: A Critical Review of Market Estimates throughout the World.” Journal of Risk and Uncertainty27(1):5–76
435. Vistnes, G. 1994. “An Empirical Investigation of Procurement Contract Structures.” Rand Journal of Economics 25(2):215–241
436. Walsh, J. P., A. Arora, and W. M. Cohen. 2003. “Working through the Patent Problem.” Science 299(5609):1021
437. Weissman, Joel S., David Blumenthal, Alvin J. Silk, Michael Newman, Kinga Zapert, Robert Leitman, and Sandra Feibelmann. 2004. “Physicians Report on Patient Encoun- ters Involving Direct-to-Consumer Advertising.” Health Affairs - Web Exclusive W4: 219–233
438. WHO. 2004. World Health Report, Revised Global Burden of Disease 2002 Estimates. London: WHO
439. WHO Collaborating Centre for Drug Statistics Methodology. 2004. “Guidelines for ATC Classification and DDD Assignment.” Oslo: Norwegian Institute
440. Widdus, Roy, and Katherine White. 2004. “Combating Diseases of Poverty: Financing Strategies for Product Development and the Potential Role of Private-Public Partner- ships.” Geneva: Initiative on Private-Public Partnerships for Health
441. Wilby, J., A. Kainth, N. Hawkins, D. Epstein, C. McDaid, et al. 2003. A Rapid and Systematic Review of the Clinical Effectiveness, Tolerability and Cost-Effectiveness of Newer Drugs for Epilepsy in Adults. Report to the National Institute for Clinical Excellence, forthcoming
442. Willan, A. R., E. M. Pinto, B. J. O’Brien, et al. 2005. “Country Specific Cost Comparisons from Multinational Clinical Trials Using Empirical Bayesian Shrinkage Estimation: The Canadian ASSENT-3 Economic Analysis.” Health Economics 14(1):327-338
443. Wittink, Richard R. 2002. “Analysis of ROI for Pharmaceutical Promotions,” September, video presentation, Association of Medical Publications. Available at www.vioworks.com/clients/amp
444. Wosinska, Marta. 2002. “Just What the Patient Ordered? Direct-to-Consumer Advertising and the Demand for Pharmaceutical Products.” Harvard Business School, Marketing Research Paper Series, No. 02-04
445. Wosinska, Marta. 2005. “Direct-to-Consumer Advertising and Drug Therapy Compli- ance.” Journal of Marketing Research 42(3):323-332
446. Wright, Brian D. 1983. “The Economics of Invention Incentives: Patents, Prizes, and Research Contracts.” American Economic Review 73:691-707
447. Zucker, LynneE., Michael R. Darby, and Marilynn B. Brewer. 1998. “Intellectual Human Capital and the Birth of U.S. Biotechnology Enterprises.” American Economic Review88(1):290-306